See more : KDDL Limited (KDDL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Collegium Pharmaceutical, Inc. (COLL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Collegium Pharmaceutical, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- International Constructions Limited (SUBCAPCITY.NS) Income Statement Analysis – Financial Results
- Base Resources Limited (BSE.AX) Income Statement Analysis – Financial Results
- Dynacons Systems & Solutions Limited (DSSL.BO) Income Statement Analysis – Financial Results
- FUJIFILM Holdings Corporation (FUJIF) Income Statement Analysis – Financial Results
- Kamat Hotels (India) Limited (KAMATHOTEL.NS) Income Statement Analysis – Financial Results
Collegium Pharmaceutical, Inc. (COLL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.collegiumpharma.com
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 566.77M | 463.93M | 276.87M | 310.02M | 296.70M | 280.41M | 28.48M | 1.71M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 240.60M | 254.45M | 126.25M | 130.18M | 193.66M | 165.68M | 2.60M | 213.00K | 171.00K | 0.00 | 0.00 |
| Gross Profit | 326.17M | 209.49M | 150.62M | 179.84M | 103.04M | 114.74M | 25.88M | 1.50M | -171.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 57.55% | 45.15% | 54.40% | 58.01% | 34.73% | 40.92% | 90.89% | 87.55% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 3.98M | 9.45M | 9.77M | 10.34M | 8.66M | 8.57M | 14.95M | 7.98M | 14.96M | 14.16M |
| General & Administrative | 151.80M | 160.44M | 114.77M | 108.46M | 0.00 | 0.00 | 0.00 | 0.00 | 18.93M | 2.71M | 1.89M |
| Selling & Marketing | 7.41M | 11.74M | 4.19M | 5.37M | 116.45M | 126.76M | 92.76M | 80.63M | 0.00 | 0.00 | 0.00 |
| SG&A | 159.21M | 172.19M | 118.96M | 113.83M | 116.45M | 126.76M | 92.76M | 80.63M | 18.93M | 2.71M | 1.89M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -94.00K | -348.00K | 0.00 | 0.00 |
| Operating Expenses | 159.21M | 176.17M | 128.41M | 123.60M | 126.79M | 135.42M | 101.33M | 95.58M | 26.91M | 17.67M | 16.04M |
| Cost & Expenses | 399.81M | 430.61M | 254.66M | 253.78M | 320.45M | 301.10M | 103.92M | 95.79M | 26.91M | 17.67M | 16.04M |
| Interest Income | 15.62M | 1.05M | 12.00K | 232.00K | 1.94M | 1.69M | 582.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 83.34M | 63.21M | 21.01M | 28.88M | 909.00K | 20.13M | 582.00K | 94.00K | 439.00K | 252.00K | 76.00K |
| Depreciation & Amortization | 149.26M | 134.39M | 68.94M | 61.61M | 15.80M | 110.91M | 594.00K | 655.00K | 171.00K | 187.00K | 169.00K |
| EBITDA | 308.33M | 168.76M | 86.58M | 118.07M | -6.02M | 91.91M | -74.27M | -93.43M | -26.65M | -17.48M | -15.95M |
| EBITDA Ratio | 54.40% | 7.41% | 8.02% | 18.21% | -7.35% | -6.78% | -262.86% | -5,498.66% | 0.00% | 0.00% | 0.00% |
| Operating Income | 166.96M | -104.57M | -46.70M | -5.09M | -23.75M | -20.69M | -75.45M | -94.08M | -26.91M | -17.67M | -16.04M |
| Operating Income Ratio | 29.46% | -22.54% | -16.87% | -1.64% | -8.00% | -7.38% | -264.95% | -5,498.66% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -91.23M | -62.17M | -21.00M | -28.65M | 1.03M | -18.44M | 582.00K | -94.00K | -348.00K | -252.00K | -155.00K |
| Income Before Tax | 75.73M | -28.85M | -3.37M | 27.58M | -22.72M | -39.13M | -74.87M | -94.18M | -27.26M | -17.92M | -16.20M |
| Income Before Tax Ratio | 13.36% | -6.22% | -1.22% | 8.90% | -7.66% | -13.95% | -262.91% | -5,504.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 27.58M | -3.85M | -74.89M | 830.00K | -14.57M | -110.91M | -1.16M | 94.00K | -91.00K | 252.00K | 79.00K |
| Net Income | 48.16M | -25.00M | 71.52M | 26.75M | -8.15M | -39.13M | -74.87M | -94.18M | -27.26M | -17.92M | -16.20M |
| Net Income Ratio | 8.50% | -5.39% | 25.83% | 8.63% | -2.75% | -13.95% | -262.91% | -5,504.15% | 0.00% | 0.00% | 0.00% |
| EPS | 1.60 | -0.74 | 2.05 | 0.78 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.40 | -2.17 |
| EPS Diluted | 1.29 | -0.74 | 1.86 | 0.76 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.40 | -2.17 |
| Weighted Avg Shares Out | 33.74M | 33.83M | 34.94M | 34.41M | 33.45M | 32.88M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
| Weighted Avg Shares Out (Dil) | 41.79M | 33.83M | 41.05M | 35.15M | 33.45M | 32.95M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion
Collegium Pharmaceutical's pain management portfolio, including Xtampza ER and Belbuca, drives 92.8% of revenues, demonstrating its market leadership in abuse-deterrent therapies. The acquisition of Jornay PM expands COLL's portfolio into neurology, tapping into the rapidly growing ADHD market, which is...
Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)
MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved JORNAY PM™, an extended-release formulation of methylphenidate, a stimulant medication for the treatment of...
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?
Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.
Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Michael Heffernan - Interim President and Chief Executive Officer, Founder and Chairman Scott Dreyer - Chief...
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings
While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street...
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago.
Collegium Reports Record Third Quarter 2024 Financial Results
– Generated Record Q3'24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca ® Revenue of $53.2 Million and Record Xtampza ® ER Revenue of $49.5 Million –
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Source: https://incomestatements.info
Category: Stock Reports